TY - JOUR
T1 - Novel mechanism of neovascularization in peritoneal dissemination via cancer-Associated mesothelial cells affected by TGF-β derived from ovarian cancer
AU - Fujikake, Kayo
AU - Kajiyama, Hiroaki
AU - YoshiHara, Masato
AU - Nishino, Kimihiro
AU - Yoshikawa, Nobuhisa
AU - Utsumi, Fumi
AU - Suzuki, Shiro
AU - Niimi, Kaoru
AU - Sakata, Jun
AU - Mitsui, Hiroko
AU - Shibata, Kiyosumi
AU - Senga, Takeshi
AU - Kikkawa, Fumitaka
PY - 2018/1
Y1 - 2018/1
N2 - Epithelial ovarian cancer (EOC) is believed to cause peritoneum dissemination through microenvironmental cell-To-cell communication between the tumor and mesothelium, leading to the further acquisition of progressive and metastatic potentials. In the present study, we aimed to determine the role of cancer-Associated mesothelial cells (CAMCs) in the promotion of tumor neovascularization and vascular permeability via enhanced vascular endothelial growth factor (VEGF) production. We examined whether a characteristic morphological change in human peritoneal mesothelial cells (HPMCs) was observed in the presence of malignant ascites and tumor-derived TGF-β. We focused on the enhanced production of VEGF in CAMCs and its crucial role in endothelial migration and tube formation. Normal HPMCs showed an epithelial morphology with a cobblestone appearance. When HPMCs were co-cultured with malignant ascites from patients with advanced EOC, a dramatic morphologic change was noted from an epithelioid pattern to an α-SMA-positive fibroblastic, mesenchymal pattern. Additionally, we found that EOC-derived TGF-β induced typical EMT-like morphological alteration in HPMCs, which was associated with CAMCs. We further discovered that CAMCs play a crucial role in the enhanced migration and tube formation of endothelial cells by the promotion of VEGF production. In conclusion, our findings indicate the possible involvement of CAMCs in the neovascularization of EOC and enhancement of vascular permeability, resulting in the formation of malignant ascites. The novel mechanism of CAMCs as a facilitator of EOC progression is displayed by microenvironmental cell-To-cell communication between EOC and the mesothelium.
AB - Epithelial ovarian cancer (EOC) is believed to cause peritoneum dissemination through microenvironmental cell-To-cell communication between the tumor and mesothelium, leading to the further acquisition of progressive and metastatic potentials. In the present study, we aimed to determine the role of cancer-Associated mesothelial cells (CAMCs) in the promotion of tumor neovascularization and vascular permeability via enhanced vascular endothelial growth factor (VEGF) production. We examined whether a characteristic morphological change in human peritoneal mesothelial cells (HPMCs) was observed in the presence of malignant ascites and tumor-derived TGF-β. We focused on the enhanced production of VEGF in CAMCs and its crucial role in endothelial migration and tube formation. Normal HPMCs showed an epithelial morphology with a cobblestone appearance. When HPMCs were co-cultured with malignant ascites from patients with advanced EOC, a dramatic morphologic change was noted from an epithelioid pattern to an α-SMA-positive fibroblastic, mesenchymal pattern. Additionally, we found that EOC-derived TGF-β induced typical EMT-like morphological alteration in HPMCs, which was associated with CAMCs. We further discovered that CAMCs play a crucial role in the enhanced migration and tube formation of endothelial cells by the promotion of VEGF production. In conclusion, our findings indicate the possible involvement of CAMCs in the neovascularization of EOC and enhancement of vascular permeability, resulting in the formation of malignant ascites. The novel mechanism of CAMCs as a facilitator of EOC progression is displayed by microenvironmental cell-To-cell communication between EOC and the mesothelium.
KW - Cancer-Associated mesothelial cells
KW - Epithelial ovarian cancer
KW - Epithelial-mesenchymal transition
KW - Neovascularization
KW - Peritoneal dissemination
KW - TGF-β-
UR - http://www.scopus.com/inward/record.url?scp=85037081713&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85037081713&partnerID=8YFLogxK
U2 - 10.3892/or.2017.6104
DO - 10.3892/or.2017.6104
M3 - Article
C2 - 29192324
AN - SCOPUS:85037081713
SN - 1021-335X
VL - 39
SP - 193
EP - 200
JO - Oncology reports
JF - Oncology reports
IS - 1
ER -